Takahashi S, Tateda K, Yanagihara K, Huang H, Doi Y, Yasuda M, Matsumoto K, Sumiya M, Takaya R, Suwada K, Kamiyabu S, Sasagawa Y, Minamida T, Kato S, Kondo K, Naruse T, Mikamo H. Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis: Integral-1, a double-blind, randomised phase 3 trial. Lancet, 2026;407:1929-1940.
Endo A, Hanai Y, Hanawa K, Namiki T, Hashi H, Asakawa D, Yokoyama Y, Maruyama R, Tsujimura S, Matsumoto K, Igarashi Y, Enoki Y, Matsumoto K. Practical Dose Ranges Supporting Target Vancomycin Exposure with AUC-Guided Dosing in Overweight and Obese Patients: A Multicentre Retrospective Study. British Journal of Clinical Pharmacology, accepted April 2026.
Iketani O, Uno S, Shinjo M, Takemura R, Fukuda S, Seyama S, Kimura M, Ishikawa H, Hayakawa T, Uwamino Y, Namkoong H, Yoshifuji A, Obara H, Takano Y, Enoki Y, Taguchi K, Sato Y, Matsumoto K, Hasegawa N. Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort study. JAC-Antimicrobial Resistance, accepted April 2026.
Suzuki A, Fujihara H, Yamaguchi F, Yoshida H, Tanaka H, Ishigo T, Fujii S, Ebihara F, Maruyama T, Yagi Y, Hamada Y, Nagumo F, Samura M, Komatsu T, Tomizawa A, Chiba H, Takuma A, Nishi Y, Igarashi Y, Enoki Y, Matsumoto K. Comparison of area under the concentration–time curve estimations between Practical Antimicrobial Therapeutic Drug Monitoring (PAT) versions 3 and 4 for vancomycin using two-point sampling. Journal of Infection and Chemotherapy, accepted May 2026.
Hosoi A, Duan S, Shimada S, Suzuki K, Mizukami Y, Shintani R, Takahashi M, Satake N, Muraishi T, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K. Three Fluoroquinolones with Different Epithelial Lining Fluid Penetration in a Murine Lung Infection Model: An Experimental Site-Specific PK/PD Study. Antimicrobial Agents and Chemotherapy, accepted May 2026.
Matsumoto Y, Mihara T, Okamoto Y, Tsubouchi A, Ikegami S, Takahashi M, Nakabayashi K, Nishimoto N, Mizukami Y, Muraishi T, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K. Comparative effectiveness and safety of 15-valent and 13-valent pneumococcal conjugate vaccines alone and in combination with the 23-valent polysaccharide vaccine: A systematic review and meta-analysis. Biological and Pharmaceutical Bulletin, accepted May 2026.
